Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma.

ABSTRACT:

SUBMITTER: Zhao SH 

PROVIDER: S-EPMC12310512 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature